Regeneron Monoclonal Antibodies Cocktail, Called Inmazeb®, Now Approved By FDA -- As Ebola Therapy...

Merck already has the leading vaccine for Ebola. This is a therapy -- for those who contract the acute form of the virus. And to be clear, this virus kills nearly all who catch it -- and aren't lucky enough to get immediate, aggressive treatment. And even then, about 6 in ten die of it. The price per dose is like to be astronomical, as compared to average annual incomes in Sub-Saharan Africa. Even so, it is very good news.

Here's the story, from last week already (so much going on):

. . . .The treatment, Inmazeb, is a combination of three genetically-engineered antibodies. The company Regeneron Pharmaceuticals developed it to treat both young and old patients with the virus version called Zaire Ebola. It is the deadliest kind of Ebola known to infect humans. Zaire Ebola usually kills 60 to 90 percent of patients.

FDA officials announced the approval of Inmazeb on Wednesday. . . .

In July 2020, Regeneron Pharmaceuticals signed a deal worth around $345 million with the US government for supplying a predetermined number of Inmazeb treatment doses. The supply will be to the Biomedical Advanced Research and Development Authority (BARDA) over the course of six years up to 2026. . . .

Now you know -- and good news. This is in fact quite similar to the cocktail given to Donald Trump on an experimental basis (for COVID).

नमस्ते